Table of contents
- Trial overview
- Who is being studied
- Trial phases and study designs
- What the trials measure
- Key trial details
- Important patient terms
Trial overview
The available studies are interventional trials, which means researchers are giving treatment plans and then measuring the results.[1][2][3] All three trials are in acute lymphoblastic leukemia (ALL), a fast-growing blood cancer.[1][2][3] Asparaginase is part of the treatment plans in these studies, but it is being tested as one element of a larger regimen, not alone.[2][3]
Who is being studied
One trial studies infants under one year of age with newly diagnosed ALL, specifically KMT2A-rearranged infant ALL.[1] Another trial includes children with ALL and confirmed activation of the JAK/STAT pathway, which is a cell-signaling pathway used to group patients for the study.[2] The third trial focuses on older adults with newly diagnosed Philadelphia-negative B-cell precursor ALL.[3]
These studies show that Asparaginase is being investigated across very different age groups.[1][2][3] The trial data also show that the researchers are looking at special subgroups, not only all people with ALL.[1][2][3]
Trial phases and study designs
The listed studies are in Phase 3 and Phase 4, which are later stages of clinical research.[1][2][3] Phase 3 trials usually compare one treatment plan with another and measure how well they work.[1][3] Phase 4 studies look at treatment use in a more real-world setting after earlier testing has already been done.[2]
One trial includes a safety run-in, which is an early safety check before the main comparison starts.[3] This helps researchers see whether the treatment plan is tolerable before they judge long-term outcomes.[3]
What the trials measure
The infant ALL study uses event-free survival (EFS) as its main endpoint, which means the time from diagnosis until a major problem such as resistance to induction, relapse, death, or a second cancer.[1] “Induction” is the first part of treatment, and resistance to induction means the leukemia does not go into complete remission by the end of that phase.[1]
The JAK/STAT pathway study measures the proportion of patients who are MRD-negative at TP2, which means no minimal residual disease is found at that time point.[2] MRD is a very small amount of leukemia that may remain even when standard tests show improvement.[2]
The older-adult study measures safety in the run-in part, then compares event-free survival and overall survival in the main phase.[3] Overall survival means the time from randomization until death from any cause.[3]
Key trial details
NCT05327894 is a Phase 3, authorised study in 276 infants under one year with acute lymphoblastic leukemia, and its main goal is to improve event-free survival compared with historical results from the Interfant06 protocol.[1]
2024-518316-39-00 is a Phase 4, authorised single-arm study in 25 children with ALL and confirmed JAK/STAT pathway activation, and it compares the MRD-negative rate at TP2 with an external control group.[2] A single-arm study means there is no direct treatment comparison group inside the trial itself.[2]
NCT04994717 is a Phase 3, authorised randomized study in 307 older adults with newly diagnosed Philadelphia-negative B-cell precursor ALL, and it compares blinatumomab alternating with low-intensity chemotherapy against standard chemotherapy.[3] The study also includes safety outcomes such as treatment-emergent adverse events, treatment-related adverse events, and adverse events of interest in the safety run-in.[3]
Important patient terms
Randomized means patients are assigned to different treatment groups by chance.[3] External control means the study compares results with data from outside the trial rather than with a built-in control group.[2] Historical results means past trial results are used as a comparison point.[1]
Authorised means the study has been approved to move forward in the listed setting.[1][2][3] Enrollment is the planned number of people who can take part in the study.[1][2][3]
